| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/08916931003782122 |
| P8608 | Fatcat ID | release_kvkoxln62bfylachtvmysiimmm |
| P932 | PMC publication ID | 2989346 |
| P698 | PubMed publication ID | 20701455 |
| P5875 | ResearchGate publication ID | 45628368 |
| P2093 | author name string | Qinghua Zhou | |
| Fu-Dong Shi | |||
| P2860 | cites work | The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo | Q24600773 |
| Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22 | Q24655076 | ||
| Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome | Q24798867 | ||
| TH17 cells in development: an updated view of their molecular identity and genetic programming | Q28276449 | ||
| Multiple immuno-regulatory defects in type-1 diabetes | Q28344695 | ||
| Natural killer type 2 bias in remission of multiple sclerosis | Q28359878 | ||
| Natural killer cells in antiviral defense: function and regulation by innate cytokines | Q33652468 | ||
| Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity | Q34331875 | ||
| How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets | Q34389470 | ||
| Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. | Q34596171 | ||
| Analysis of islet inflammation in human type 1 diabetes. | Q34917032 | ||
| Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? | Q35451574 | ||
| Natural killer cells trigger differentiation of monocytes into dendritic cells | Q36007747 | ||
| Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells | Q36380889 | ||
| CD4+CD25+ Tregs and NKT cells: regulators regulating regulators | Q36492658 | ||
| Th17: an effector CD4 T cell lineage with regulatory T cell ties | Q36510274 | ||
| Reciprocal regulation between natural killer cells and autoreactive T cells | Q36602589 | ||
| T(H)-17 cells in the circle of immunity and autoimmunity | Q36765453 | ||
| IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice | Q37036086 | ||
| Th17 cell differentiation: the long and winding road | Q37133442 | ||
| Critical regulation of early Th17 cell differentiation by interleukin-1 signaling | Q37250727 | ||
| Can NK cells be a therapeutic target in human type 1 diabetes? | Q37315687 | ||
| Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. | Q37343849 | ||
| Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules | Q39225213 | ||
| Target cell defense prevents the development of diabetes after viral infection. | Q40741831 | ||
| Cytokines induce the development of functionally heterogeneous T helper cell subsets | Q41732572 | ||
| Protective role of NK1.1+ cells in experimental Staphylococcus aureus arthritis | Q44560701 | ||
| Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses | Q45345593 | ||
| Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. | Q46092585 | ||
| Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells | Q46231038 | ||
| NKG2D blockade prevents autoimmune diabetes in NOD mice | Q46294168 | ||
| The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system | Q48554549 | ||
| Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. | Q50764796 | ||
| A role for natural killer cells in the immunopathogenesis of multiple sclerosis. | Q50876710 | ||
| CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. | Q53015646 | ||
| Altered natural killer cells in type 1 diabetic patients. | Q54565253 | ||
| Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1) | Q56908797 | ||
| Autoreactive T Cells Mediate NK Cell Degeneration in Autoimmune Disease | Q63363292 | ||
| Natural killer cells determine the outcome of B cell–mediated autoimmunity | Q63363347 | ||
| Autoimmunity mediated by innate immune effector cells | Q74068325 | ||
| Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B | Q77951822 | ||
| IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis | Q79755041 | ||
| CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation | Q80967934 | ||
| Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming | Q80975562 | ||
| Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis | Q81672078 | ||
| Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma | Q81685771 | ||
| Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis | Q81733254 | ||
| Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis | Q82136598 | ||
| Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis | Q84565920 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 3-10 | |
| P577 | publication date | 2010-08-11 | |
| P1433 | published in | Autoimmunity | Q4826348 |
| P1476 | title | Natural killer cells as indispensable players and therapeutic targets in autoimmunity | |
| P478 | volume | 44 |
| Q41457829 | Alterations of natural killer cells in traumatic brain injury |
| Q38840151 | Cross-Disease Transcriptomics: Unique IL-17A Signaling in Psoriasis Lesions and an Autoimmune PBMC Signature |
| Q30410722 | Cutting edge: Ly49C/I⁻ neonatal NK cells predispose newborns to autoimmune ovarian disease induced by maternal autoantibody |
| Q34062618 | Identification of human NK17/NK1 cells |
| Q38156767 | Initial immunopathogenesis of multiple sclerosis: innate immune response. |
| Q51725094 | KIR2DL2 and KIR2DS2 as genetic markers to the methotrexate response in rheumatoid arthritis patients. |
| Q51332483 | Microfluidic-Based Live-Cell Analysis of NK Cell Migration In Vitro. |
| Q39171809 | Microfluidic-based, live-cell analysis allows assessment of NK-cell migration in response to crosstalk with dendritic cells |
| Q40107170 | Multiparameter flow cytometry for discovery of disease mechanisms in rheumatic diseases |
| Q35905953 | Natural killer cells: role in local tumor growth and metastasis |
| Q34329075 | On the role of natural killer cells in neurodegenerative diseases |
| Q58692418 | Role of Natural Killer Cells in Multiple Sclerosis |
Search more.